Hormones, weight loss, and the context of midlife

# Hormones, weight loss, and the context of midlife OCTOBER 15, 2026 | LONGEVITY SPECIAL Women who took menopause hormone therapy while on semaglutide lost more weight than women who did not, according to The Menopause Society's report of a new study. The researchers also say it is too early to act on the finding. Responses to treatment unfold within a changing physiology. An observational finding about menopause hormone therapy and semaglutide asks whether that context helps explain differences in weight loss. This article is based on that report. The study paper itself was not reviewed. Midlife women are among the heaviest users of GLP-1 weight loss drugs. According to The Menopause Society, about one in five women aged 50 to 64 report current or past use of a GLP-1 obesity medication. That is the highest share of any U.S. demographic group, the society says. Weight gain is a common worry in this stage of life. The Menopause Society notes that midlife gains are largely driven by aging. Menopause-related factors can also add to fat accumulation and change where fat is stored. The new study looked at whether hormone therapy changes how women respond to these drugs. According to The Menopause Society's report, it was a retrospective observational cohort study. That means researchers looked back at existing records rather than assigning women to treatments. It included nearly 2,400 women taking semaglutide and nearly 1,500 taking tirzepatide. All were over 45 with a BMI above 27. Semaglutide acts on one gut hormone pathway, called GLP-1. Tirzepatide acts on that pathway and a second one. According to the report, the researchers concluded that hormone therapy was associated with significantly greater and sustained weight loss with semaglutide. With tirzepatide, women using hormone therapy initially lost more weight. By the end, the difference did not reach statistical significance. In plain terms, the gap with tirzepatide could not be separated from chance. The report does not give effect sizes. It does not say how many pounds more women on hormones lost, so the size of the difference is unknown from this source. Lead author Dr. Regina Castaneda of Mayo Clinic Florida called it a consistent signal. She noted that earlier, smaller studies pointed the same way. She said it is biologically plausible, citing preclinical data that suggest estrogen and GLP-1 signaling may work together. She also said the stronger effect with semaglutide deserves further study. She was equally clear about the limits. "It is too early to draw firm conclusions," she said, according to the report. She said the findings need confirmation in well-designed prospective trials. She also stressed that weight loss is not an indication for menopause hormone therapy. That caution matters for personal decisions. An observational study shows an association. Women who use hormone therapy may differ from those who do not in ways the study cannot fully account for. The report does not describe how the researchers handled such differences, and the paper was not available to check. The finding does not show that hormones caused the extra weight loss. Dr. Stephanie Faubion, medical director of The Menopause Society, said the findings suggest hormone therapy may influence how some women respond to GLP-1-based weight loss medications. She said more research is needed. She added that the study highlights the importance of considering menopause-specific factors when developing personalized approaches to weight management for midlife women. Our reading of the practical takeaway is narrow, and it is our own inference, not a recommendation from the researchers. Castaneda's caution that weight loss is not an indication for hormone therapy points the same way. Do not start or stop hormone therapy or a GLP-1 medication without talking to your clinician first. The study will be presented at The Menopause Society's 2026 Annual Meeting in San Diego, October 20-24. The full data, including effect sizes, and prospective trials would be needed to show whether the link holds. A prospective study could test the interaction more directly. The possibility is a more precise understanding of treatment response, with benefits and risks considered together. Source: The Menopause Society The Menopause Society: https://menopause.org/press-releases/hormone-therapy-may-increase-weight-loss-effectiveness-of-glp-1s ---